Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 4Waldenstrom Macroglobulinemia 3Rectal Neoplasms 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Colonic Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Lymphocytic, Chronic, B-Cell 2Intraocular Lymphoma 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Unspecified Childhood Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Docetaxel 277Prednisone 237enzalutamide 177Leuprolide 172Radiotherapy 164Abiraterone Acetate 154Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 79abiraterone 77gallium 68 PSMA-11 74Specimen Handling 67darolutamide 58Gonadotropin-Releasing Hormone 58Radiation 56Triptorelin Pamoate 53cabazitaxel 50Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × Enzyme-Linked Immunosorbent Assay × Clear all
NCT01385059 2023-03-07

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

City of Hope Medical Center

Phase 2 Completed
11 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT01270880 2018-09-18

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
18 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡